 | Up a level |
Zelceski, Anabel; Francica, Paola; Lingg, Lea; Mutlu, Merve; Stok, Colin; Liptay, Martin; Alexander, John; Baxter, Joseph S; Brough, Rachel; Gulati, Aditi; Haider, Syed; Raghunandan, Maya; Song, Feifei; Sridhar, Sandhya; Forment, Josep V; O'Connor, Mark J; Davies, Barry R; van Vugt, Marcel A T M; Krastev, Dragomir B; Pettitt, Stephen J; ... (2023). MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells. Cell reports, 42(5), p. 112484. Cell Press 10.1016/j.celrep.2023.112484
Borst, Gerben R; Kumareswaran, Ramya; Yücel, Hatice; Telli, Seyda; Do, Trevor; McKee, Trevor; Zafarana, Gaetano; Jonkers, Jos; Verheij, Marcel; O'Connor, Mark J; Rottenberg, Sven; Bristow, Robert G (2017). Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model. OncoTarget, 8(50), pp. 87638-87646. Impact Journals LLC 10.18632/oncotarget.20936
Oplustil O'Connor, Lenka; Rulten, Stuart L; Cranston, Aaron N; Odedra, Rajesh; Brown, Henry; Jaspers, Janneke E; Jones, Louise; Knights, Charlotte; Evers, Bastiaan; Ting, Attilla; Bradbury, Robert H; Pajic, Marina; Rottenberg, Sven; Jonkers, Jos; Rudge, David; Martin, Niall M B; Caldecott, Keith W; Lau, Alan; O'Connor, Mark J (2016). The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models. Cancer research, 76(20), pp. 6084-6094. American Association for Cancer Research AACR 10.1158/0008-5472.CAN-15-3240
